Heparin induced thrombocytopenia: Review

Expert Review of Hematology

Volumn 6, Issue 4, 2013, Pages 419-428

  Dasararaju, Radhika ^a   Singh, Nirupama ^a   Mehta, Amitkumar ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

4T score; argatroban; danaparoid; desirudin; fondaparinux; heparin; heparin induced thrombocytopenia; HIT; lepirudin; thrombocytopenia

Indexed keywords

HEPARIN; HUMANS; RISK FACTORS; THROMBOCYTOPENIA;

EID: 84894212416     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.814446     Document Type: Review

References (77)

1. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparininduced thrombocytopenia. Circulation 111(20), 2671-2683 (2005).
2. Sachais BS, Rux AH, Cines DB et al. Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood 119(25), 5955-5962 (2012).
3. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 120(20), 4160-4167 (2012).
4. Strauss R, Wehler M, Mehler K et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit. Care Med. 30(8), 1765-1771 (2002).
5. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch. Intern. Med. 164(18), 1961-1964 (2004).
6. Kelton JG. Heparin-induced thrombocytopenia: an overview. Blood Reviews 16(1), 77-80 (2002).
7. Martel NJ, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106(8), 2710-2715 (2005).
8. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332(20), 1330-1335 (1995).
9. Warkentin TE. Fondaparinux: Does it cause HIT? Can it treat HIT? Expert Rev. Hematol. 3(5), 567-581 (2010).
10. Francis JL, Palmer GJ, Moroose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann. Thorac. Surg. 75(1), 17-22 (2003).
11. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J. Lab. Clin. Med. 128(4), 376-383 (1996).
12. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparininduced thrombocytopenia in a large, tertiary care teaching hospital. Chest 131(6), 1644-1649 (2007).
13. Warkentin TE, Sheppard JA, Sigouin CS et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108(9), 2937-2941 (2006).
14. Cuker A, Cines DB. How I treat heparininduced thrombocytopenia. Blood 119(10), 2209-2218 (2012).
15. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit. Care Med. 35(4), 1165-1176 (2007).
16. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Crit. Care Clin. 27(4), 805-823 (2011).
17. Chong BH. Heparin-induced thrombocytopenia. J. Thromb. Hemost. 1(7), 1471-1478 (2003).
18. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin. Thromb. Hemost. 30(3), 273-283 (2004).
19. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), e24S-43S (2012).
20. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparininduced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Invest. 93(1), 81-88 (1994).
21. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 91(3), 916-922 (1998).
22. Ziporen L, Li ZQ, Park KS et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 92(9), 3250-3259 (1998).
23. Li ZQ, Liu W, Park KS et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 99(4), 1230-1236 (2002).
24. Newman PM, Chong BH. Heparininduced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 96(1), 182-187 (2000).
25. Kelton JG, Sheridan D, Santos A et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 72(3), 925-930 (1988).
26. Reilly RF. The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin. Dialysis 16(1), 54-60 (2003).
27. Warkentin TE, Hayward CP, Boshkov LK et al. Sera from patients with heparininduced thrombocytopenia generate plateletderived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84(11), 3691-3699 (1994).
28. Kasthuri RS, Glover SL, Jonas W et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcgammaRI. Blood 119(22), 5285-5293 (2012).
29. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98(4), 1252-1254 (2001).
30. Krauel K, Weber C, Brandt S et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood 120(16), 3345-3352 (2012).
31. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb. J. 3, 14 (2005).
32. Warkentin TE Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344(17), 1286-1292 (2001).
33. Lubenow N, Kempf R, Eichner A et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122(1), 37-42(2002).
34. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann. Int. Med. 135(7), 502-506 (2001).
35. Nand S, Wong W, Yuen B et al. Heparininduced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am. J. Hematol. 56(1), 12-16 (1997).
36. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101(5), 502-507 (1996).
37. Warkentin TE, Sheppard JA, Horsewood P et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96(5), 1703-1708 (2000).
38. Baroletti S, Hurwitz S, Conti NA et al. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am. J. Med. 125(1), 44-49 (2012).
39. Rosenberger LH, Smith PW, Sawyer RG et al. Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. Crit. Care Med. 39(4), 833-838 (2011).
40. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101(8), 3049-3051 (2003).
41. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparininduced thrombocytopenia. Am. J. Hematol. 76(3), 240-244 (2004).
42. Warkentin TE, Elavathil LJ, Hayward CP et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Int. Med. 127(9), 804-812 (1997).
43. Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu. Rev. Med. 50, 129-147 (1999).
44. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation 110(18), e454-e458 (2004).
45. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit. Care Med. 32(4), 976-980 (2004).
46. Lo GK, Juhl D, Warkentin TE et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J. Thromb. Haemost. 4(4), 759-765 (2006).
47. Cuker A, Arepally G, Crowther MA et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J. Thromb. Haemost. 8(12), 2642-2650 (2010).
48. Sheridan D, Carter C, Kelton J. A diagnostic test for heparin-induced thrombocytopenia. Blood 67(1), 27-30 (1986).
49. LaMuraglia GM, Houbballah R, Laposata M. The identification and management of heparin-induced thrombocytopenia in the vascular patient. J. Vasc. Surg. 55(2), 562-570 (2012).
50. Denomme GA, Warkentin TE, Horsewood P et al. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa 'low responder' (his131) gene in patients with heparin-induced thrombocytopenia. J. Lab. Clin. Med. 130(3), 278-284 (1997).
51. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch. Pathol. Lab. Med. 126(11), 1415-1423 (2002).
52. Althaus K, Hron G, Strobel U et al. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb. Res. 131(3), e85-e90 (2013).
53. Cines DB, Bussel JB, McMillan RB, Zehnder JL. Congenital and acquired thrombocytopenia. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 390-406 (2004).
54. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzymeimmunoassays. J. thromb. haemost. 6(8), 1304-1312 (2008).
55. Warkentin TE. HITlights: a career perspective on heparin-induced thrombocytopenia. Am. J. Hematol. 87(Suppl. 1), S92-S99 (2012).
56. Gurbuz AT, Elliott WG, Zia AA. Heparininduced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines. Eur. J. Cardio-Thorac. 27(1), 138-149 (2005).
57. Wallis DE, Workman DL, Lewis BE et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am. J. Med. 106(6), 629-635 (1999).
58. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch. Intern. Med 164(4), 361-369 (2004).
59. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Intern. Med. 163(15), 1849-1856 (2003).
60. Keeling D. Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Brit. J. Haematol. 133(3), 259-269 (2006).
61. Linkins LA, Dans AL, Moores LK et al. Treatment and prevention of heparininduced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), e495S-530S (2012).
62. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96(3), 846-851 (2000).
63. Greinacher A, Janssens U, Berg G et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 100(6), 587-593 (1999).
64. Greinacher A, Volpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99(1), 73-80 (1999).
65. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A, Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 104(10), 3072-3077 (2004).
66. Greinacher A, Lubenow N, Eichler P, Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108(17), 2062-2065 (2003).
67. Bambrah RK, Pham DC, Zaiden R, Vu H, Tai S. Heparin-induced thrombocytopenia. Clin. Adv. Hematol. Onc. 9(8), 594-599 (2011).
68. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 101(1), 31-37 (2003).
69. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103(14), 1838-1843 (2001).
70. Saugel B, Phillip V, Moessmer G, Schmid RM, Huber W. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study. Crit. Care (London, England) 14(3) R90 (2010).
71. Motokawa S, Torigoshi T, Maeda Y et al. IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics. BMC Musculoskeletal Disorders 12, 22 (2011).
72. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology/the Education Program of the American Society of Hematology. Am. Soc. Hematol. Education Program 497-519, (2003).
73. Bakchoul T, Greinacher A. Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. Therap. Adv. Hematol. 3(4), 237-251 (2012).
74. Warkentin TE. HIT paradigms and paradoxes. J. Thromb. Haemost. 9(Suppl. 1), 105-117 (2011).
75. Warkentin TE, Greinacher A. Heparininduced thrombocytopenia and cardiac surgery. Ann. Thorac. Surg. 76(2), 638-648 (2003).
76. Krauel K, Hackbarth C, Furll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 119(5), 1248-1255 (2012).
77. Kelton JG, Warkentin TE. Heparininduced thrombocytopenia: a historical perspective. Blood 112(7), 2607-2616 (2008).